- Home
- QLGN vs PRFX Comparison
QLGN vs PRFX Comparison
Compare QLGN & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- PRFX
- Stock Information
- Founded
- QLGN 1996
- PRFX 2007
- Country
- QLGN United States
- PRFX Israel
- Employees
- QLGN N/A
- PRFX N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- PRFX Biotechnology: Pharmaceutical Preparations
- Sector
- QLGN Health Care
- PRFX Health Care
- Exchange
- QLGN Nasdaq
- PRFX Nasdaq
- Market Cap
- QLGN 3.1M
- PRFX 2.8M
- IPO Year
- QLGN N/A
- PRFX 2020
- Fundamental
- Price
- QLGN $1.90
- PRFX $1.35
- Analyst Decision
- QLGN
- PRFX Hold
- Analyst Count
- QLGN 0
- PRFX 1
- Target Price
- QLGN N/A
- PRFX N/A
- AVG Volume (30 Days)
- QLGN 125.5K
- PRFX 92.2K
- Earning Date
- QLGN 08-26-2025
- PRFX 08-29-2025
- Dividend Yield
- QLGN N/A
- PRFX N/A
- EPS Growth
- QLGN N/A
- PRFX N/A
- EPS
- QLGN N/A
- PRFX N/A
- Revenue
- QLGN N/A
- PRFX N/A
- Revenue This Year
- QLGN N/A
- PRFX N/A
- Revenue Next Year
- QLGN N/A
- PRFX N/A
- P/E Ratio
- QLGN N/A
- PRFX N/A
- Revenue Growth
- QLGN N/A
- PRFX N/A
- 52 Week Low
- QLGN $1.61
- PRFX $1.25
- 52 Week High
- QLGN $11.50
- PRFX $16.63
- Technical
- Relative Strength Index (RSI)
- QLGN 32.76
- PRFX 42.03
- Support Level
- QLGN $1.61
- PRFX $1.32
- Resistance Level
- QLGN $1.91
- PRFX $1.55
- Average True Range (ATR)
- QLGN 0.16
- PRFX 0.08
- MACD
- QLGN -0.01
- PRFX 0.01
- Stochastic Oscillator
- QLGN 26.48
- PRFX 38.46
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.